Note: Check with our organization’s library for availability.
A. “Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial,” by Tali Cukierman-Yaffe, Hertzel C. Gerstein, Helen M. Colhoun, Rafael Diaz, Luis-Emilio García-Pérez, Mark Lakshmanan, Angelyn Bethel, Denis Xavier, Jeffrey Probstfield, Matthew C. Riddle, Lars Rydén, Charles Messan Atisso, Stephanie Hall, Purnima Rao-Melacini, Jan Basile, William C. Cushman, Edward Franek, Matyas Keltai, Fernando Lanas, Lawrence A. Leiter, Patricio Lopez-Jaramillo, Valdis Pirags, Nana Pogosova, Peter J. Raubenheimer, Jonathan E. Shaw, Wayne H-H Sheu, and Theodora Temelkova-Kurktschiev (Vol. 19, No. 7, July 2020, p. 582-590).
www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30173-3/fulltext
B. “Safety and immunogenicity of the{alpha}α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial,” by Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, Petra Lührs, Caroline Thun-Hohenstein, Achim Schneeberger, Gergana Galabova, Nour Majbour, Nishant Vaikath, Omar El-Agnaf, Dorian Winter, Eva Mihailovska, Andreas Mairhofer, Carsten Schwenke, Günther Staffler, and Rossella Medori (Vol. 19, No. 7, July 2020, p. 591-600).
www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30136-8/fulltext
